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Abstract
Purpose: To investigate the reproducibility of LIRADS v2014 and contribute to its widespread use in clinical practice.
Material and methods: This retrospective, single-centre study was conducted between January 2010 and October 2015. 
A total of 132 patients who had dynamic magnetic resonance imaging (MRI)/computed tomography (CT) images in 
the Picture Archiving and Communication Systems (PACS) with liver nodule were included in the study, 37 of whom 
had histopathology results. Five radiologists who participated in the study, interpreted liver nodules independently 
on different PACS stations according to the LIRADS reporting system and its main parameters.
Results: We determined that level of inter-observer agreement in the LR-1, LR-5, and LR-5V categories was higher 
than in the LR-2, LR-3, and LR-4 categories (κ = 0.522, 0.442, and 0.600 in the LR-1, LR-5, and LR-5V categories, 
respectively; κ = 0.082, 0.298, and 0.143 in the LR-2, LR-3, and LR-4 categories, respectively). The parameter that we 
observed to have the highest level of inter-observer agreement was venous thrombus (κ = 0.600).
Conclusions: Our study showed that LIRADS achieves an acceptable inter-observer reproducibility in terms of clinical 
practice although it is insufficient at intermediate risk levels. We think that the prevalence of its use will be further 
increased with training related to the subject and the assignment of numerical values that express the probability of 
malignancy for each category and including the ancillary features in the algorithm according to clearer rules.
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Introduction
Hepatocellular carcinoma (HCC) is increasing in frequen-
cy all over the world [1]. It is the sixth most commonly 
occurring cancer in the world and the third greatest cause 
of cancer mortality [2]. Risk factors have been demon-
strated well enough, and early diagnosis is possible with 
suitable surveillance. Early diagnosis allows curative treat-
ment opportunities. 
Recently published diagnostic guidelines utilise the 
imaging modalities more than ever. Due to biopsy-related 
complications, including haemorrhage, inadequate sam-
pling in small lesions, and seeding along the biopsy tract, 
the American Liver Diseases Association (AASLD) recom-
mends biopsy only for lesions greater than 1 cm in diameter 
and suspicious radiological findings [3-6]. The result is the 
increasing responsibility of radiologists in HCC diagnosis.
For several years great effort has been devoted to the 
study of HCC diagnosis and treatment. The decision to be 
made between diagnosis and treatment, as in all diseases, 
is vital to the prognosis of the disease. One of the parame-
ters that make these decisions accurate is the correct com-
munication. The communication expressed in this sense 
should ensure that the diagnostic information could be 
transferred to the clinician with an effective method. Diag-
nostic classifications have been developed for this purpose.
Although there is some conflict on the pathognomon-
ic imaging features of HCC, there is no single algorithm 
accepted in the physician-radiologist axis. The Liver Im-
aging Reporting and Data System (LIRADS), introduced 
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by American College of Radiology (ACR) in 2011, aims 
to fill this gap in the field. However, it has not gained as 
wide currency as the Breast Imaging Reporting and Data 
Systems (BIRADS) developed for reporting breast lesions. 
Nonetheless, several centres around the world have begun 
to utilise LIRADS as a reporting tool. This trend has been 
increasing as the reliability rises and the practicability of 
the method is accepted more. 
Studies that investigate the effectiveness of LIRADS in 
clinical practice are limited [7-10]. One of the questions 
that we think is important in this regard is: What is the 
level of alignment between observers in evaluations made 
with LIRADS? Indication of a high level of reproducibility 
will lead to widespread use of these classifications. 
The purpose of this study was to investigate the repro-
ducibility of LIRADS v2014 and contribute to its wide-
spread use in clinical practice.
Material and methods
This retrospective study was approved by the Institution-
al Review Board (IRB; 2609-GOA/09-10/2016) and was 
conducted in accordance with the ethical standards of 
the Institutional and National Research Committee and 
with the 1964 Helsinki Declaration and its later amend-
ments.
Patients admitted to our hospital between January 
2010 and October 2015 were involved in the study. We 
considered only those patients who had cirrhosis due to 
any cause and had a dynamic contrast-enhanced com-
puted tomography (CT) or magnetic resonance imaging 
(MRI) examination for further downstream analysis.
A total of 2398 cirrhosis patients with International 
Classification of Disease code 10 (ICD-10) were extract-
ed using hospital information system. One of the authors 
of the study reviewed all the cases and eliminated 2077 
patients who had no contrast-enhanced dynamic series. 
Also 151 patients lacking liver lesions and 38 patients with 
suboptimal examination quality were removed from the 
study. The most identifiable lesion in different series and 
sequences was selected. A total of 132 lesions were final-
ly listed with their identification numbers, demographic 
data, lesion localisation by liver segments, and the exam-
ination dates, to be review by the observers.
Lesions smaller than 1 cm in diameter are not recom-
mended for dynamic contrast imaging; therefore, patients 
under 18 years old and patients with suboptimal image 
quality were excluded from the study. In addition, the 
patients received any kind of treatment previously, were 
excluded from the study. 
Five observers with more than five years of radiology 
experience evaluated the lesions. Images were interpreted 
independently on different PACS stations. Observers were 
blind to the clinical and pathological findings. 
The presence of threshold growth, arterial contrast 
enhancement, washout, pseudocapsule appearance and 
vascular thrombus were evaluated for each lesion. Meas-
urement of the nodules was done in the best visualised 
sequence and phase concerning the longest diameter. Mi-
nor parameters were also taken into consideration in the 
LIRADS class allocation. 
Classification criteria were downloaded from the offi-
cial ACR website. The LIRADS v2014 reporting algorithm 
was used in nodule reporting. 
All of the MRI examinations were performed in the 
Department of Radiology of our hospital with the use of 
Achieva (Philips Medical Systems, Best, The Netherlands) 
and Intera (Philips Medical Systems, Best, The Nether-
lands) 1.5-Tesla MRI equipment. Precontrast images in-
cluded the DWI series, fast spin echo (FSE) fat-suppressed 
axial T2-weighted, axial T2-weighted images with sin-
gle-shot FSE technique, and GRE T1-weighted out-phase/
in-phase axial images. Post-contrast dynamic images were 
acquired in late arterial, portal, and late portal phases with 
breath-hold spoiled-GRE 3D technique in axial and coro-
nal planes. Subtracted images were obtained from dynam-
ic series in order to make a more price interpretation. All 
the cases have DWI axial images and ADC maps obtained 
from the same data sets. 
MRI acquisition parameters included FOV: 385-415 mm, 
matrix: 256 × 256, slice thickness: 8 mm, fat-sat T2-weight-
ed axial images (TSE SPIR, TR: 1500-2350 ms, TE: 70 ms, 
ETL: 24), T2 star axial images (TSE SSH, TR: 1300-1500 ms, 
TE: 325 ms, ETL: 144), T1-weighted dual phase axial imag-
es (GRE T1 DUAL, TR: 96-138, TE: 4.6/2.3, ETL: 2, FA: 10-
150), DWI axial images (SE EPI SENSE DWI B = 0 sn/mm2, 
B = 5000 sn/mm2, B = 10,000 sn/mm2), pre- and post-con-
trast fat-sat axial and coronal images (Breath-Hold 3D 
GRE sTHRIVE/TFE-IP/WATS T1, TR: 230-251 ms, TE: 
4.6-6.9 ms, ETL: 1, FA: 10-150), and subtracted images ob-
tained from these data. 
CT images of the patients consisted of arterial and 
portal phase images acquired with “Philips Brilliance” 
(16 and 64 slice) equipment using parameters of KVP: 
120, mA: 280-400, FOV: 385-410 mm, matrix: 512 × 512, 
and pitch: 1-1.5 with 2 mm slice thickness. Precontrast 
imaging was skipped in order not to increase the patient 
radiation dose. 
Gadolinium-based contrast materials (Dotarem, 
Gadovist, Multihance, Omniscan, Magnevist, Primovist) 
and iodine containing contrast agents (Omnipaque, Optiray, 
Pamiray, Ultravist) were used in MRI and CT examinations, 
respectively. Contrast material admission was given via pe-
ripheral veins at 3-5 cc/s. Late arterial, portal, and venous 
phase images were taken after 35-40, 60-70, and 180-350 
seconds, respectively. 
100 ml of iodinated contrast medium (density of 300 mg/ 
ml) for dynamic CT and 10 ml of gadolinium contrast 
agent (density of 0.1 mmol/ml) for dynamic MR were 
injected intravenously, followed by normal saline flush 
(20 ml). Using the bolus-tracking method, the late arte-
rial phase was scanned when the contrast media passed 
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the portal vein. Late arterial, portal, and delayed hepatic 
phases were obtained according to recommended techni-
cal specifications in the LI-RADS guidelines [11]. 
Statistical evaluation
Statistical analyses were done by means of SPSS v20.0 
(IBM, Chicago, USA) software. The significance of the 
statistical analysis results was evaluated in 95% CIP-values 
less than 0.05 were considered as significant.
Maximum and minimum values, arithmetic mean, 
standard deviation, and frequencies were calculated in 
descriptive analysis.
Intraclass correlation analysis was performed in order 
to compare the observer’s liver nodule diameter measure-
ments. χ2 test was performed to compare different pro-
portions. 
κ-analysis was used to evaluate the inter-observer re-
producibility between major specifications of LIRADS 
and final LIRADS classification. Cohen’s κ for two-fold 
and Fleiss’s κ for more than two inter-observer con-
formity was calculated. The Landis & Koch scale; 0-0.20 
(harmonious compliance), 0.21-0.40 (poor compliance), 
0.41-0.60 (moderate compliance), 0.61-0.80 (good com-
pliance), and 0.81-1.00 (perfect fit) was utilised to evaluate 
κ-values [12].
Results
In total 132 cases who had dynamic contrast CT/MRI 
examinations were included in the study. Ninety-two 
(69.79%) and 40 (30.3%) of the cases were men and wom-
en, respectively. Mean age was 58.77 ± 11.09 years, and no 
statistical significance was found between genders accord-
ing to the age averages (p = 0.822). Thirty-seven (28.0%) 
of the cases were evaluated with CT, and 95 (72.0%) of the 
study group were evaluated with MRI.
ICC was found (95% CI: 0.756 [0.696-0.811]) for the 
nodule diameter measurements of all observers.
Fleiss’s κ value was used to evaluate inter-observer re-
producibility for arterial contrast enhancement, washout, 
pseudocapsule appearance, threshold growth, and ve-
nous thrombus, which were the major parameters in the 
LIRADS reporting system. Fleiss’s κ was calculated for 
arterial contrast enhancement, washout, pseudocapsule 
appearance, threshold growth, and thrombus as 0.414, 
0.471, 0.494, 0.575, and 0.600, respectively. 
Contrast enhancement patterns in 62 of the lesions were 
concluded after an inter-observer consensus. The number of 
the nodules in which the observers were in consensus ac-
cording to washout, pseudocapsule appearance, threshold 
growth, and venous thrombus were 61, 77, 18, and 
109, respectively. Threshold growth assessment was not 
possible with cases who had no previous examinations. 
The best agreed parameter between observers was venous 
thrombus.
When the final LIRADS classes were evaluated by the 
observers, Fleiss’s κ values ranged from 0.442 to 0.600 in 
LR-5, LR-5V, and LR-1 classes. These results were accept-
able for clinical practise. However, it was noted that the 
inter-observer agreement was lower in the intermediate 
categories LR-2, LR-3, and LR-4 for the HCC risk grade. 
Only 10 of all nodules were classified as LR-1 consensus 
by the observers, while the consensus nodule number of 
the observers was 12 in the LR-5 class and 6 in the LR-5V 
class. However, there were no consensus-reported nodules 
in the LR-2, LR-3, and LR-4 classes among the observers. 
When all the LIRADS classes were evaluated together, 
it was found that the inter-observer reproducibility was 
weaker (κ = 0.392). Only 28 (21.2%) of all nodules had 
consensus among the observers in the determination of 
final LIRADS class of liver nodules (Table 1).
When the major parameters and categories of LIRADS 
were evaluated according to the modality, the level of re-
producibility in CT for arterial contrast enhancement was 
higher than in MRI. A higher compliance score was found 
on MRI compared to CT in assessing washout, pseudocap-
sule findings, venous thrombosis, and threshold growth.
Table 1. The analysis evaluation results of liver nodules according to the LIRADS reporting system by observers and inter-observer reproducibility levels in 
LIRADS categories
LIRADS Ob-1
n (%)
Ob-2
n (%)
Ob-3
n (%)
Ob-4
n (%)
Ob-5
n (%)
Con
n (%)
κ
 (95% CI)
LR-1 30 (22.73%) 21 (15.91%) 40 (30.30%) 32 (24.24%) 37 (28.03%) 10 (35.71%) 0.522 (0.468-0.575)
LR-2 12 (9.09%) 23 (17.42%) 8 (6.06%) 1 (0.76%) 8 (6.06%) 0 (0%) 0.082 (0.028-0.135)
LR-3 17 (12.88%) 20 (15.15%) 8 (6.06%) 12 (9.09%) 14 (10.61%) 0 (0%) 0.298 (0.244-0.352)
LR-4 15 (11.36%) 11 (8.33%) 13 (9.85%) 24 (18.18%) 9 (6.82%) 0 (0%) 0.143 (0.089-0.197)
LR-5 32 (24.24%) 34 (25.76%) 48 (36.36%) 48 (36.36%) 51 (38.64%) 12 (42.86%) 0.442 (0.388-0.496)
LR-5V 24 (18.18%) 22 (16.67%) 15 (11.36%) 14 (10.61%) 8 (6.06%) 6 (21.43%) 0.600 (0.546-0.654)
LR-M 2 (1.52%) 1 (0.76%) 0 (0%) 1 (0.76%) 5 (3.79%) 0 (0%) 0.268 (0.214-0.322)
Total 132 (100%) 132 (100%) 132 (100%) 132 (100%) 132 (100%) 28 (100%) 0.392 (0.366-0.418)
Ob – observer, κ– Fleiss’s kappa, Con – consensus, n – number of nodules, LR – LIRADS
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Observational correlation was found to be stronger 
in CT of the nodule diameter measurement (ICC = 0.833 
and 0.676). The level of inter-observer reproducibility in 
all LIRADS classes was found to be higher in CT (Table 2).
Discussion
The best inter-observer reproducibility was found in LR-5, 
LR-5V, and LR-1; lesions in these classes can be catego-
rised with little doubt of their benign or malign proba-
bility. However, it was found to be low in LR-2, LR-3, and 
LR-4 lesions, which are more important in the surveil-
lance of cirrhotic patients. Unfortunately, we think that 
the reason was poor level of reproducibility in all LIRADS 
classes we observed in our study. 
In the study of Davenport et al. a poor reproducibility 
level (κ = 0.35) was found for LIRADS when they com-
pared some similar reporting systems. They found the 
highest level in LR-5/5V and LR-1 classes (κ = 0.62 and 
0.54, respectively). The reproducibility level was low 
in LR-2, LR-3, and LR-4 classes, similarly to our study 
(κ = 0.11, 0.26, and 0.28, respectively) [13]. Schellhaas 
et al. [14] observed good reproducibility for all LIRADS 
categories in the study they conducted using only MRI 
(κ = 0.609). However, they performed the study with only 
two observers [14]. In the multicentre prospective study 
by Basha et al. 296 liver lesions were followed-up clini-
cally and radiologically every six months, classified using 
LIRADS v2014 by six observers. They observed κ-values 
for venous thrombus, arterial hyperenhancement, wash-
out appearance, and capsule appearance 0.983, 0.621, 
0.546, and 0.549 by CT; 0.991, 0.649, 0.674, and 0.742 by 
MRI, respectively. They found a good level of reproduc-
ibility for all LIRADS classes (κ = 0.895 by CT and 0.926 
by MRI) [15].
The LIRADS guide published by ACR recommends 
radiological follow-up for LR-2 and LR-3 nodules. LR-4 
nodules require a different approach, and the guide rec-
ommends further clinical and radiological evaluation in 
multidisciplinary case discussion sessions. Biopsy should 
only be performed as a result of multidisciplinary discus-
sion [11].
Although there are a limited number of studies that 
question the malignancy probability in LIRADS classes, 
in a study by Burke et al. [16] it was shown that 30.9% of 
LR-4 nodules progressed to LR-5 in a median 163-day fol-
low-up [16]. In another study by Tanabe et al. [17], nod-
ules were followed 614 days on average, and they found 
that 4% of LR-3 and 38% of LR-4 nodules progressed to 
LR-5 [17]. Darnell et al. [18] designed to evaluate the 
sensitivity and specificity of LIRADS, and suggested that 
96% of LR-4 nodules, which were smaller than 20 mm 
in diameter and followed up within a six-month period, 
were HCC histopathologically. This percentage was 98 
for LR-5 nodules [18]. We believe that LR-4 nodules have 
to be evaluated and managed as LR-5 nodules due to the 
high risk of malignancy and low level of inter-observer 
reproducibility for this category of nodules. 
In our study, we found a medium level of reproduc-
ibility (κ = 0.414-0.600) for the major parameters of the 
LIRADS reporting system. These were in accord with the 
results of similar research [13,19].
We found a higher correlation for CT than for MRI 
(0.483 and 0.387, respectively) in the evaluation of arterial 
contrast enhancement. However, inter-observer correla-
tion was higher with MR than with CT in the evaluation 
of washout (0.525 and 0.336). Subtracted images in the 
MRI series could be responsible for this result. 
It is generally expected that MRI is superior to CT 
in pseudocapsule interpretation [20]. Ehman et al. [21] 
found a higher sensitivity in the observation of pseudo-
capsule and higher inter-observer correlation with MRI 
(44% and 0.62) compared to CT (31% and κ = 0.56) [21]. 
Kappa values for pseudocapsule were very close to each 
other for MRI and CT in our study (0.487 and 0.412, re-
spectively). However, this may be deceptive because of the 
low number of cases detectable with CT, which influences 
the sample size and changes the Cohen’s κ values. 
In our study, we did not address the effect of the ancillary 
features because use of the ancillary features is subjective and 
difficult to reproduce but can affect nodule categorisation. 
We suggest that depicting the role of ancillary features more 
explicitly in the LIRADS algorithm could reduce this effect.
In contrast to similar reporting systems, LIRADS has 
an illustrative atlas with detailed criteria of categories. 
Table 2. Inter-observer reproducibility values according to radiological 
examination modality in LIRADS classes and major parameters. The kappa 
value (κ) for categorical variables and the intraclass correlation coefficient 
(ICC) for the nodule diameter were calculated to determine the level of 
inter observer compliance
Factor Fleiss’s κ (95% CI) ICC (95% CI)
Arterial contrast 
enhancement
MRI 0.387 (0.322-0.451) –
CT 0.483 (0.381-0.584) –
Washout MRI 0.525 (0.460-0.590) –
CT 0.336 (0.233-0.440) –
Pseudocapsule 
appearance
MRI 0.487 (0.422-0.552) –
CT 0.412 (0.306-0.518) –
Threshold growth MRI 0.600 (0.454-0.746) –
CT 0.452 (0.175-0.729) –
Venous thrombus MRI 0.607 (0.544-0.671) –
CT 0.570 (0.468-0.671) –
LIRADS MRI 0.368 (0.337-0.399) –
CT 0.441 (0.389-0.494) –
Diameter MRI – 0.676
 (0.593-0.754)
CT – 0.833
 (0.737-0.908)
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This allows a standard instructional curriculum. We be-
lieve that such an educational course will improve the ac-
curacy of reporting and the inter-observer reliability level. 
LIRADS, which was developed for similar reasons, 
offers a numeric probability range for the malignancy of 
the lesions. LIRADS currently does not accept this quanti-
tative approach. Multi-centric statistical studies with large 
groups using the LIRADS classification will make use this 
quantitative assessment, which will improve the clinical 
use of this reporting system. 
Our study showed that LIRADS achieves an acceptable 
inter-observer reproducibility in terms of clinical practice, 
although the consistency at intermediate-risk levels is in-
sufficient. This result is trustworthy in terms of further use 
of classification. We think that the prevalence of its use will 
be further increased with training related to the subject 
and the assignment of the numerical values, which express 
the probability of malignancy for each category, and in-
cluding the ancillary features in the algorithm according 
to clearer rules.
Limitations
Our study has some limitations. These are the retrospec-
tive nature, the relatively small sample size, and the sin-
gle-centre design. In some multicentric studies higher re-
producibility levels for LI-RADS were found [15,22,23]. 
Also, all MRI examinations were performed with an 
extracellular gadolinium contrast agent, and we did not 
evaluate the liver-specific contrast media. 
In our department, LIRADS has not been routinely used 
by the observers; therefore, the observers needed a special 
training session prior to the study to become familiar with 
the use of LIRADS. Davenport et al. [13] showed that in-
terobserver agreement for all LIRADS classes and its main 
parameters was better in experienced readers [13].
Conclusions
In our study, there were small differences in MR scanning 
parameters and in the rate of injection of contrast media. 
This may reflect selection biases and differences between 
the imaging protocols. However, all imaging examinations 
satisfied the recommended technical specifications in the 
LI-RADS system. Also, the trends observed in this study 
may be considered as more generalisable based on the 
heterogeneous study population.
In our study, the observers evaluated the cases blind to 
clinical and laboratory data. Having these data could im-
prove the precision of decision and increase the inter-ob-
server reproducibility. 
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